Synopsys Cash & Equivalents decreased by 18.6% to $43.11M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 98.8%, from $3.66B to $43.11M. Over 5 years (FY 2020 to FY 2025), Cash & Equivalents shows a downward trend with a -46.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher levels indicate strong liquidity and financial flexibility; lower levels may signal potential cash flow issues.
This represents the most liquid assets held by the company, including cash on hand, demand deposits, and short-term inve...
A universal metric for assessing a company's immediate financial health.
cash_and_equivalents| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.46B | $1.39B | $1.44B | $1.13B | $1.58B | $1.39B | $1.42B | $1.16B | $1.54B | $1.68B | $1.44B | $1.12B | $1.51B | $1.84B | $3.90B | $3.66B | $14.12B | $2.53B | $52.98M | $43.11M |
| QoQ Change | — | -5.0% | +3.4% | -21.5% | +39.9% | -12.1% | +2.5% | -18.5% | +33.3% | +9.1% | -14.7% | -22.3% | +34.8% | +22.4% | +111.7% | -6.2% | +286.1% | -82.1% | -97.9% | -18.6% |
| YoY Change | — | — | — | — | +7.9% | -0.1% | -1.1% | +2.7% | -2.1% | +21.4% | +1.2% | -3.5% | -2.4% | +9.4% | +171.5% | +227.7% | +838.3% | +37.5% | -98.6% | -98.8% |